# Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma

> **NCT04077515** · PHASE4 · COMPLETED · sponsor: **Children's Hospital of Fudan University** · enrollment: 92 (actual)

## Conditions studied

- Hemangioma
- Kaposiform Hemangioendothelioma

## Interventions

- **DRUG:** Sirolimus(0.8mg/m2)
- **DRUG:** Sirolimus(0.7mg/m2)

## Key facts

- **NCT ID:** NCT04077515
- **Lead sponsor:** Children's Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2022-12-10
- **Final completion:** 2022-12-31
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04077515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04077515, "Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04077515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*